Swiss pharma giant Roche said it will invest $50 billion in the US over the next five years, in one of the biggest inward investment moves by companies dealing with President Donald Trump’s tariffs policy.
Roche said the investment would create more than 12,000 new jobs, including nearly 6,500 construction jobs, as well as 1,000 jobs at new and expanded facilities.
Drugs makers are announcing investments to counter tariffs by the Trump administration, which is seeking to boost domestic manufacturing.
Roche’s investment follows an announcement by fellow Swiss drugmaker Novartis, which earlier this month said it will spend $23 billion in the US on expanding existing and building new facilities.
Roche said its investment will include new research and development sites as well as expanded manufacturing facilities in Indiana, Pennsylvania, Massachusetts and California.
Once all new and expanded manufacturing capacity comes on-line, Roche will export more medicines from the US than it imports, the company said.
Chief executive Thomas Schinecker said the investment underscored the company’s commitment to the US.
“Our investments of $50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US. and around the world,” he said in a statement.
